Revelation Biosciences Inc Net Assets
Revelation Biosciences Inc net assets. Based on the latest financial reports, Revelation Biosciences Inc (REVB) has net assets worth $10.07 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.50 Million) and total liabilities ($2.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore REVB net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.07 Million |
| % of Total Assets | 80.55% |
| Annual Growth Rate | -27.92% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 201.81 |
Net Assets of Revelation Biosciences Inc (2016–2025)
Net assets of Revelation Biosciences Inc from 2016 to 2025. This chart illustrates how Revelation Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See REVB equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Revelation Biosciences Inc (2016–2025)
The table below shows the annual net assets of Revelation Biosciences Inc from 2016 to 2025. For live market cap and overall valuation, see Revelation Biosciences Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.86 Million | +88.20% |
| 2024-12-31 | $4.71 Million | -29.17% |
| 2023-12-31 | $6.65 Million | +531.64% |
| 2022-12-31 | $1.05 Million | +1158.06% |
| 2021-12-31 | $-99.47K | -100.15% |
| 2020-12-31 | $67.82 Million | +1864236.78% |
| 2019-12-31 | $-3.64K | -100.00% |
| 2018-12-31 | $264.89 Million | +40.69% |
| 2017-12-31 | $188.28 Million | +11.57% |
| 2016-12-31 | $168.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revelation Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 363.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Revelation Biosciences Inc Net Assets Breakdown (December 2025)
Revelation Biosciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.58K | 0.02% |
| Other Components | $58.28 Million | 657.70% |
| Total Equity | $8.86 Million | 100.00% |
Revelation Biosciences Inc Competitors by Market Cap
The table below lists competitors of Revelation Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Largo SAS
PA:ALLGO
|
$4.03 Million |
|
Pragma Inkaso S.A.
WAR:PRI
|
$4.03 Million |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
$4.03 Million |
|
Fluicell AB
ST:FLUI
|
$4.04 Million |
|
PREMIER1 Lithium Ltd
AU:PLC
|
$4.02 Million |
|
International Biotechnology Trust plc
LSE:IBT
|
$4.02 Million |
|
OMG Group Ltd
AU:OMG
|
$4.02 Million |
|
SIXTY SIX CAPITAL INC.
F:5CR0
|
$4.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revelation Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,708,382 to 8,860,995, a change of 4,152,613 (88.2%).
- Net loss of 8,913,649 reduced equity.
- Dividend payments of 5,951,528,000 reduced retained earnings.
- New share issuances of 3,388,244 increased equity.
- Other factors increased equity by 5,961,206,018.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.91 Million | -100.59% |
| Dividends Paid | $5.95 Billion | -67165.46% |
| Share Issuances | $3.39 Million | +38.24% |
| Other Changes | $5.96 Billion | +67274.68% |
| Total Change | $- | 88.20% |
Book Value vs Market Value Analysis
This analysis compares Revelation Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-6.72 | $4.43 | x |
| 2020-12-31 | $375698.28 | $4.43 | x |
| 2021-12-31 | $-169.29 | $4.43 | x |
| 2022-12-31 | $58.57 | $4.43 | x |
| 2023-12-31 | $465.20 | $4.43 | x |
| 2024-12-31 | $27.45 | $4.43 | x |
| 2025-12-31 | $14.27 | $4.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revelation Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.31x
- Recent ROE (-100.59%) is above the historical average (-142.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 5.20% | 17.98% | 0.03x | 11.22x | $-8.10 Million |
| 2017 | 8.64% | 21.99% | 0.04x | 11.15x | $-2.56 Million |
| 2018 | 10.43% | 32.46% | 0.03x | 9.27x | $1.14 Million |
| 2019 | 0.00% | 0.00% | 4226.19x | 0.00x | $-3.27K |
| 2020 | -0.20% | 0.00% | 0.00x | 1.09x | $-6.92 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.98 Million |
| 2022 | -1028.98% | 0.00% | 0.00x | 5.23x | $-10.93 Million |
| 2023 | -1.81% | 0.00% | 0.00x | 1.84x | $-785.03K |
| 2024 | -319.40% | 0.00% | 0.00x | 1.41x | $-15.51 Million |
| 2025 | -100.59% | 0.00% | 0.00x | 1.31x | $-9.80 Million |
Industry Comparison
This section compares Revelation Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revelation Biosciences Inc (REVB) | $10.07 Million | 5.20% | 0.24x | $4.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more